Dabomb Protein Biotech (ROCO:6578) Debt-to-Equity : 0.35 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Dabomb Protein Biotech Debt-to-Equity?

Dabomb Protein Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$276.3 Mil. Dabomb Protein Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$76.3 Mil. Dabomb Protein Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$1,012.5 Mil. Dabomb Protein Biotech's debt to equity for the quarter that ended in Mar. 2024 was 0.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dabomb Protein Biotech's Debt-to-Equity or its related term are showing as below:

ROCO:6578' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.34 Max: 0.92
Current: 0.35

During the past 11 years, the highest Debt-to-Equity Ratio of Dabomb Protein Biotech was 0.92. The lowest was 0.09. And the median was 0.34.

ROCO:6578's Debt-to-Equity is ranked better than
54.38% of 1644 companies
in the Consumer Packaged Goods industry
Industry Median: 0.41 vs ROCO:6578: 0.35

Dabomb Protein Biotech Debt-to-Equity Historical Data

The historical data trend for Dabomb Protein Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dabomb Protein Biotech Debt-to-Equity Chart

Dabomb Protein Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.23

0.42

0.92

0.68

0.44

Dabomb Protein Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.74	0.58	0.56	0.44	0.35

Competitive Comparison of Dabomb Protein Biotech's Debt-to-Equity

For the Packaged Foods subindustry, Dabomb Protein Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dabomb Protein Biotech's Debt-to-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dabomb Protein Biotech's Debt-to-Equity falls into.

Dabomb Protein Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dabomb Protein Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(331.665	+	86.337)	/	958.063
	=	0.44

Dabomb Protein Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(276.3	+	76.282)	/	1012.462
	=	0.35

Dabomb Protein Biotech (ROCO:6578) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dabomb Protein Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dabomb Protein Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dabomb Protein Biotech (ROCO:6578) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Dabomb Protein Biotech Corp (ROCO:6578) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Number 52, Gongye 3rd Road, Annan District, Tainan, TWN, 709

Website

https://www.dabombprotein.com

Dabomb Protein Biotech Corp is a company specializing in antibiotic alternatives, and use postbiotics to boost immune strength and excel in innovative fermentation for improved plant protein utility. Their portfolio of products which include DBT-100 LS and DBT-100 HT , Liqui-TIDE bandage and LACTOTIDES HEALTH A+.

Dabomb Protein Biotech (ROCO:6578) Headlines

No Headlines